The present invention relates to an intensification of the synthetic process for the preparation of dialkyl ether from alcohol by using a conical fixed bed reactor integrated with distillation coupled conical polishing reactor.

The present invention relates to an intensification of the synthetic process for the preparation of dialkyl ether from alcohol by using a conical fixed bed reactor integrated with distillation coupled conical polishing reactor.

A process for producing an ether including treating (a) an ester with (b) hydrogen in the presence of (c) a heterogeneous catalyst to reduce the ester by hydrogenation to form an ether product.

A process for producing an ether including treating (a) an ester with (b) hydrogen in the presence of (c) a heterogeneous catalyst to reduce the ester by hydrogenation to form an ether product.

A process for dehydrating C.sub.2+ alcohols to ether products in the presence of a catalyst and promoter, wherein the catalyst is at least one aluminosilicate zeolite catalyst which is a medium pore zeolite having a 3-dimensional framework structure, and the promoter is one or more organic carbonyl compounds or derivatives thereof, and wherein and the molar ratio of promoter to C.sub.2+ alcohols is maintained at less than 1.

A process for dehydrating C.sub.2+ alcohols to ether products in the presence of a catalyst and promoter, wherein the catalyst is at least one aluminosilicate zeolite catalyst which is a medium pore zeolite having a 3-dimensional framework structure, and the promoter is one or more organic carbonyl compounds or derivatives thereof, and wherein and the molar ratio of promoter to C.sub.2+ alcohols is maintained at less than 1.

The invention relates to novel crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole (Maribavir), pharmaceutical compositions thereof and their use in medical therapy.

The invention relates to novel crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole (Maribavir), pharmaceutical compositions thereof and their use in medical therapy.

A method for forming a blend of ethers from a blend of alcohols includes a step of reacting a hydrocarbon-containing gas with an oxygen-containing gas to form first product blend. The first product blend includes a blend of partially oxygenated compounds. The blend of partially oxygenated compounds is provided to a reactive distillation station where it is converted a second product blend. The second product blend typically includes a mixture of ethers. An apparatus implementing the method is also provided.

A method for forming a blend of ethers from a blend of alcohols includes a step of reacting a hydrocarbon-containing gas with an oxygen-containing gas to form first product blend. The first product blend includes a blend of partially oxygenated compounds. The blend of partially oxygenated compounds is provided to a reactive distillation station where it is converted a second product blend. The second product blend typically includes a mixture of ethers. An apparatus implementing the method is also provided.